openPR Logo
Press release

Leukemia Therapeutics Market to Hit $27.78 Billion by 2027 Driven By key Players - Sanofi/ Genzyme Corporation, F. Hoffmann-La Roche, Johnson & Johnson Services, Inc., Amgen Inc., Novartis 

11-23-2021 01:41 PM CET | Health & Medicine

Press release from: Fortune Business Insights™ Pvt. Ltd.

Leukemia Therapeutics Forecast 2021-2028

Leukemia Therapeutics Forecast 2021-2028

Leukemia Therapeutics 2021 Covers A Detailed Study of the Leukemia Therapeutics Size, Growth, And Share, Trends, Consumption, Segments, Application and Forecast 2028.

***Get Latest Updated Market Research Report with Sample Report

Market Overview

The global leukemia therapeutics market size is projected to reach USD 27.78 billion by 2028, exhibiting a CAGR of 8.1% during the forecast period. The increasing demand for enhanced treatments for blood cancers amid the COVID-19 pandemic will accelerate the market, states Fortune Business Insights™ in its report, titled “Leukemia Therapeutics Market Size, Share & Industry Analysis, By Type of Leukemia (Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), and Others), By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Others), By Route of Administration (Oral Mode and Injectable Mode), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, and Others), and Regional Forecast, 2021-2028”.

Request for Sample Report PDF @ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/leukemia-therapeutics-market-104754

List of Key Companies Covered in the Leukemia Therapeutics Market Report:

Sanofi/ Genzyme Corporation (Paris, France)
Hoffmann-La Roche (Basel, Switzerland)
Johnson & Johnson Services, Inc. (New Brunswick, U.S.)
Amgen Inc. (Thousand Oaks, U.S.)
Novartis (Basel, Switzerland)
Takeda Pharmaceutical Co Ltd (Tokyo, Japan)
Bristol-Myers Squibb (New York, U.S.)
AbbVie (North Chicago, U.S.)
Lupin Ltd. (India, Mumbai)
Pfizer Inc. (New York, U.S.)

Cancer patients are at a heightened risk of contracting the coronavirus and likely to experience severe effects of the infection due to their weakened immune systems. According to a study conducted by the UK Coronavirus Cancer Monitoring Project (UKCCMP), patients with leukemia, multiple myeloma, and lymphoma are highly susceptible to COVID-19 and leukemia patients have twice the chance of dying from the virus. The study found that patients with blood cancer are 57% more likely to experience severe symptoms of COVID-19 than patients with other types of cancers. Given these and other similar findings, the demand for leukemia therapeutics has been soaring during the COVID-19 pandemic, with market players reporting increased sales. Bristol-Myers Squibb, for instance, announced that the sales of Sprycel, its treatment for chronic myeloid leukemia (CML) jumped 14% to USD 521 million in the first quarter of 2020. However, the disruption in the medical supply chain will lead the market to register a lower growth rate of 6.2% and touch a value of USD 16.15 billion in 2020.

As per the report findings, the estimated value of the global market stood at USD 15.21 billion in 2019. The main highlights of the report include:

Calculated estimations about the upcoming trends and prospects in the market;
Path-breaking research into the regional dynamics of the market;
Comprehensive study of the factors driving and restraining the market; and
Careful profiling and diagnosis of the key market players and their dominant strategies.
Restraining Factors

Debilitating Side Effects of Chemotherapy May Hinder Market Growth

Chemotherapy is one of the most potent leukemia therapeutics and has emerged as the most powerful and the most commonly recommended treatment for most types of cancers. Chemo drugs are designed to attack and kill fast-growing cells, and since cancer cells proliferate rapidly, these medications speedily eliminate them. However, because chemo medicines travel throughout the body, they end up killing healthy cells, leading to side effects that can considerably weaken the patient, albeit temporarily. For example, chemotherapy can harm the blood cells in the bone marrow, where red blood cells (RBCs) are manufactured. With RBC production disrupted, the patient is likely to experience moderate to severe anemia, which in turn can cause symptoms such as fatigue, lightheadedness, and general weakness. Furthermore, chemo can also harm the production of white blood cells (WBCs), the body’s soldiers that fight infections. As a result, cancer patients become extremely susceptible to infections and even a minor bout of cough & cold can prove detrimental for them. Thus, the known side effects of chemotherapy may hamper the leukemia therapeutics market growth.

Regional Insights

North America to Foster Stable Market Growth Backed by High Healthcare Expenditure

North America is expected to dominate the leukemia therapeutics market share during the forecast period as the USA and Canada have sharply increased their spending on healthcare technologies and infrastructure in the past few decades. Moreover, policymakers in the two countries are taking constant efforts to expand healthcare coverage, especially for cancer patients. In 2019, the region’s market size stood at USD 6.92 billion.

Europe is poised to emerge as the second-largest market for leukemia therapeutics due to the increasing number of leukemia patients in the continent. In the UK, for instance, leukemia accounted for 3% of all cancer cases in the country in 2017, according to Cancer Research UK. The market in Asia Pacific, on the other hand, will experience prolific growth owing to the improving health reimbursement policies in China and India.

Competitive Landscape

Regulatory Support for Innovative Therapies to Raise Market Potential

Key players in this market are enjoying a period of consistent support for their offerings by regulatory bodies such as the US Food and Drug Administration (FDA). Such support will play an instrumental role in managing leukemia symptoms in patients and the criticality of leukemia therapeutics is likely to rise as cancer prevalence grows worldwide.

Industry Developments:

October 2020: The US FDA cleared AbbVie’s VENCLEXTA treatment in combination with azacitidine, or decitabine, or low-dose cytarabine. The therapy is indicated for treating acute myeloid leukemia (AML) in adults aged 75 years and above or those with comorbidities who cannot undergo intensive chemotherapy.
September 2020: Bristol Myers Squibb secured the US FDA’s approval for its Onuregfor the continued treatment of adult patients with AML. The treatment is designed for those patients who have attained the first complete remission or remission with incomplete blood recovery following intensive chemo.

Ask for Customization @ https://www.fortunebusinessinsights.com/enquiry/customization/leukemia-therapeutics-market-104754

Continued. . .

NOTE: Our team is studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. We aim to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

LinkedIn: https://www.linkedin.com/company/fortune-business-insights

Facebook: https://www.facebook.com/FortuneBusinessInsightsPvtLtd

Twitter: https://twitter.com/FBInsightPvtLtd

308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Leukemia Therapeutics Market to Hit $27.78 Billion by 2027 Driven By key Players - Sanofi/ Genzyme Corporation, F. Hoffmann-La Roche, Johnson & Johnson Services, Inc., Amgen Inc., Novartis  here

News-ID: 2471765 • Views:

More Releases from Fortune Business Insights™ Pvt. Ltd.

Global Dermatophytic Onychomycosis Treatment Market Size Covered By Global Analy …
Market Overview The global dermatophytic onychomycosis treatment market size is predicted to reach USD 6.63 billion by 2028, exhibiting a CAGR of 7.4% during the forecast period. The rising prevalence of diabetes and incidences of chronic nail fungus infection will lead to heavy demand for dermatophytic onychomycosis treatment, which, in turn, will foster the growth of the market, it is mentioned in a report, titled "Dermatophytic Onychomycosis Treatment Market Size, Share
Global Wound Care Market Size Covered By Global Analysis, Share, Segment, Type, …
Market Overview A comprehensive analysis of the various factors and parameters is carried out to present the report on the global Wound Care Market. The marker concentration in the global market as well as the revenue that is earned from the different market segments that comprise the Wound Care Market have been identified and are evaluated in the report. The market status from the year 2022 to the year 2028 that
Telerehabilitation Market: Collaborative Efforts by Hinge Health Inc., Doctor on …
Market Overview: The global telerehabilitation market size is poised to rise remarkably in the coming years attributable to the technological advancements in the field of healthcare services in collaboration with information, technology, and communications. Telerehabilitation is a medical service for people preferring to stay at home and avail treatment and services. As per a recent report by Fortune Business Insights, titled, "Telerehabilitation Market Size, Share and Industry Analysis By Type (Products,
Coronary Stents Market 2020 Trends, Market Share, Industry Size, Opportunities, …
Market Overview: The global coronary stents market size is projected to reach USD 8.08 billion by the end of 2027. High investment in technological intervention has opened up a huge potential for market growth. According to a report published by Fortune Business Insights, titled "Coronary Stents Market Size, Share and Global Trend by Deployment (Self and Balloon-expandable), Stent Type (Drug Eluting Stent, Bioresorbable Stent, Bare Metal Stent, Covered Stent and Others),

All 5 Releases


More Releases for Leukemia

Pipeline Review, H2 2017 of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic …
"Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- '
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, T …
Orbisreserach.Com Adds “H1 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Market Pipeline Review 2017 Trend Analysis Report Report” To Its Research Database Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape. Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the
Acute Lymphoblastic Leukemia (ALL) Market grows with high incidence of acute lym …
Acute lymphoblastic leukemia (ALL) is a cancer of white blood cells called as lymphocytes in bone marrow. It is a malignant disease in which early precursor lymphoid cells proliferate and replace the normal hematopoietic cells of bone marrow. ALL is the most common type of cancer in children. There is overproduction of lymphoblasts in the bone marrow when a person suffers from ALL that continuously multiply, damaging the bone marrow
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Tri …
ReportsWorldwide has announced the addition of a new report title Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth